dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 2, 2026

Mizuho resets view on Snowflake stock after CRO change

View original at finance.yahoo.com
Mizuho resets view on Snowflake stock after CRO change Snowflake (SNOW) stock is starting to look interesting again. Shares are down about 30% this year while the company has just appointed a new chief revenue officer as it tries to reaccelerate growth and improve sales execution…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • JB has been a key driver of our success for the past ten years, and has consistently proven his ability to deliver results at scale

    60% confidence

  • Mizuho sees over 40% upside for Snowflake stock with $220 price target

    60% confidence

  • The next question is whether Q1 results show stable pipeline trends and continued customer expansion under the new CRO

    60% confidence

  • Product revenue growth in the second half of FY2026 coming in lighter than expected

    60% confidence

  • A leadership change introduces near-term risks to pipeline continuity, deal timing, and expansion motion, just as the company tries to turn product momentum into usage growth

    60% confidence

  • JB has been a key driver of Snowflake's success for the past ten years and has consistently proven his ability to deliver results at scale

    60% confidence

  • Leadership change introduces near-term risks to pipeline continuity, deal timing, and expansion motion, just as the company tries to turn product momentum into usage growth

    60% confidence

  • Mizuho sees over 40% upside for Snowflake stock with $220 price target

    60% confidence

Data points we hold from this source

Snowflake Inc. · analyst target price239 USD
Snowflake Inc. · enterprise value50 USD
Snowflake Inc. · forward pe ratio84.3 ratio
Snowflake Inc. · implied upside55 percent
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Mizuho resets view on Snowflake stock after CRO change: Source | Via News | fr.via.news